Recently, Dizal (Jiangsu) Pharmaceutical Co., Ltd. officially filed an application for listing on the Hong Kong Stock Exchange, aiming to debut on the Main Board. Founded in 2017 as a joint venture between AstraZeneca and SDIC CTF Investment Management, Dizal is a biopharmaceutical company focused on developing innovative therapies for major diseases such as cancer, autoimmune disorders, and inflammatory conditions, with an emphasis on first-in-class or best-in-class global drug candidates.The company’s lead pipeline includes two late-stage clinical candidates: DZD4205 and DZD9008. DZD4205 is a highly selective JAK1 inhibitor currently in a pivotal Phase II trial for peripheral T-cell lymphoma (PTCL). DZD9008 is a targeted therapy for non-small cell lung cancer (NSCLC) harboring EGFR exon20 insertion mutations and has received Breakthrough Therapy Designation from both China’s National Medical Products Administration (NMPA) and the U.S. FDA. Beyond these, Dizal maintains a robust early-stage portfolio spanning hematologic malignancies, solid tumors, and immune-mediated diseases.The proposed Hong Kong listing is expected to broaden Dizal’s access to international capital and accelerate its global clinical development and commercialization strategies. If successful, the IPO would position Dizal as another prominent Chinese innovator in the global biopharma landscape, highlighting the growing competitiveness of homegrown drug developers on the world stage.
近日，迪哲（江苏）医药股份有限公司正式向香港联合交易所递交了上市申请，拟在港交所主板挂牌上市。作为一家专注于创新药物研发的生物医药企业，迪哲医药由阿斯利康与国投创合于2017年共同孵化成立，聚焦肿瘤、自身免疫及炎症等重大疾病领域，致力于开发具有全球潜力的first-in-class或best-in-class新药。公司核心产品管线包括DZD4205和DZD9008两款处于临床后期阶段的候选药物。其中，DZD4205是一种高选择性JAK1抑制剂，正在开展针对外周T细胞淋巴瘤（PTCL）的II期关键性临床试验；DZD9008则是一款针对EGFR exon20插入突变的非小细胞肺癌（NSCLC）靶向药，已获得中国国家药监局和美国FDA的突破性疗法认定。此外，迪哲医药还拥有多个早期研发项目，布局覆盖血液瘤、实体瘤及免疫疾病等多个方向。此次赴港上市，不仅有助于公司进一步拓展国际融资渠道，也将加速其全球临床开发与商业化进程。若成功上市，迪哲医药有望成为又一家登陆资本市场的中国创新药企代表，彰显本土生物医药企业在国际化道路上的强劲实力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/20627.html